GLP-1 drugs for weight management in prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests if a GLP-1 receptor agonist (a type of diabetes drug that helps with weight loss) can help men with prostate cancer who are on hormone therapy (ADT) and have a high body mass index (BMI). It aims to see if it improves their health and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer.
- You are currently taking or planning to start hormone therapy (ADT).
- Your BMI is 30 or higher, or 27 or higher if you also have high blood pressure, type 2 diabetes, sleep apnea, or high cholesterol.
- You are at least 18 years old.
- You do not have type 1 diabetes.
- You have not taken a GLP-1 drug before.
- You have no history of pancreatitis, medullary thyroid cancer, or a related genetic condition (MEN2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking semaglutide before prostate removal surgery can help men with intermediate-risk prostate cancer and high BMI. The treatment is given for 3-6 months before surgery.
This trial tests if a GLP-1 receptor agonist (a type of diabetes medication) can help treat psoriatic arthritis in people who are overweight but do not have diabetes. You might join if you have psoriatic arthritis, a high BMI, and you are of Chinese descent.
This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.
This trial tests if semaglutide, a medicine used for diabetes and weight loss, can help people with both psoriasis and obesity. You may qualify if you have moderate to severe psoriasis, a high body weight, and are of Chinese descent.
This study tests two different medicines (empagliflozin or semaglutide) added to your usual insulin to see if they help with blood sugar control and weight loss in people with type 1 diabetes who are overweight or have obesity. It may be a good fit if your diabetes is not well controlled with insulin injections alone.
This trial tests whether a diabetes medication called a GLP-1 receptor agonist (semaglutide) can help people with Duchenne muscular dystrophy manage weight and reduce metabolic complications like high blood pressure and high cholesterol. The medication may help protect heart and metabolic health in this population.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.